Company intelligence / Profile preview

Febit Biotech

Heidelberg, Germany

Ownership: Private
Employees: ~80
Development stage: Other

Overview

Febit was a biotechnology company specializing in automated DNA and RNA analysis through its proprietary Geniom platform. The company focused on the development of microRNA-based biomarkers for the early detection of diseases, including various cancers and neurological disorders. Febit's technology integrated synthesis, hybridization, and detection within a single microfluidic device, enabling high-throughput genomic research. Following financial restructuring, the company's core assets and intellectual property related to microRNA were acquired by the Comprehensive Biomarker Center (CBC) in 2010.

Therapeutic areas: OncologyNeurology
Modalities: microRNADNA microarrays
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Febit Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Febit Biotech.

Explore the full profile